440 related articles for article (PubMed ID: 8895161)
1. Clinical significance of specific autoantibodies in juvenile dermatomyositis.
Feldman BM; Reichlin M; Laxer RM; Targoff IN; Stein LD; Silverman ED
J Rheumatol; 1996 Oct; 23(10):1794-7. PubMed ID: 8895161
[TBL] [Abstract][Full Text] [Related]
2. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Srivastava P; Dwivedi S; Misra R
Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
[TBL] [Abstract][Full Text] [Related]
3. A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Targoff IN; Mamyrova G; Trieu EP; Perurena O; Koneru B; O'Hanlon TP; Miller FW; Rider LG; ;
Arthritis Rheum; 2006 Nov; 54(11):3682-9. PubMed ID: 17075819
[TBL] [Abstract][Full Text] [Related]
4. Immunoserological aspects of idiopathic inflammatory muscle disease.
Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T
Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of autoantibody screening in patients with autoimmune myositis.
Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
[TBL] [Abstract][Full Text] [Related]
7. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups.
Sarkar K; Weinberg CR; Oddis CV; Medsger TA; Plotz PH; Reveille JD; Arnett FC; Targoff IN; Genth E; Love LA; Miller FW
Arthritis Rheum; 2005 Aug; 52(8):2433-8. PubMed ID: 16052581
[TBL] [Abstract][Full Text] [Related]
8. Immune manifestations of inflammatory muscle disease.
Targoff IN
Rheum Dis Clin North Am; 1994 Nov; 20(4):857-80. PubMed ID: 7855326
[TBL] [Abstract][Full Text] [Related]
9. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy.
Rider LG; Gurley RC; Pandey JP; Garcia de la Torre I; Kalovidouris AE; O'Hanlon TP; Love LA; Hennekam RC; Baumbach LL; Neville HE; Garcia CA; Klingman J; Gibbs M; Weisman MH; Targoff IN; Miller FW
Arthritis Rheum; 1998 Apr; 41(4):710-9. PubMed ID: 9550481
[TBL] [Abstract][Full Text] [Related]
10. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein.
Espada G; Maldonado Cocco JA; Fertig N; Oddis CV
J Rheumatol; 2009 Nov; 36(11):2547-51. PubMed ID: 19833756
[TBL] [Abstract][Full Text] [Related]
11. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
[TBL] [Abstract][Full Text] [Related]
12. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
13. Clinical and serologic features of patients with polymyositis or dermatomyositis.
Holden DJ; Brownell AK; Fritzler MJ
Can Med Assoc J; 1985 Mar; 132(6):649-53. PubMed ID: 3872156
[TBL] [Abstract][Full Text] [Related]
14. Penicillamine induced polymyositis and dermatomyositis.
Carroll GJ; Will RK; Peter JB; Garlepp MJ; Dawkins RL
J Rheumatol; 1987 Oct; 14(5):995-1001. PubMed ID: 3501473
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Kaji K; Fujimoto M; Hasegawa M; Kondo M; Saito Y; Komura K; Matsushita T; Orito H; Hamaguchi Y; Yanaba K; Itoh M; Asano Y; Seishima M; Ogawa F; Sato S; Takehara K
Rheumatology (Oxford); 2007 Jan; 46(1):25-8. PubMed ID: 16728436
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
[TBL] [Abstract][Full Text] [Related]
17. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
18. [Myositis-specific autoantibodies and their clinical significance].
Suzuki S
Brain Nerve; 2011 Nov; 63(11):1197-203. PubMed ID: 22068472
[TBL] [Abstract][Full Text] [Related]
19. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
20. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
Kao AH; Lacomis D; Lucas M; Fertig N; Oddis CV
Arthritis Rheum; 2004 Jan; 50(1):209-15. PubMed ID: 14730618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
